Boundless Bio, Inc.
Clinical-stage oncology company targeting ecDNA in oncogene amplified cancers.
BOLD | US
Overview
Corporate Details
- ISIN(s):
- US10170A1007
- LEI:
- Country:
- United States of America
- Address:
- 10955 ALEXANDRIA WAY, 92121 SAN DIEGO
- Website:
- https://boundlessbio.com/
- Sector:
- Manufacturing
Description
Boundless Bio, Inc. is a clinical-stage precision oncology company focused on developing therapies for patients with oncogene amplified cancers. The company's approach is centered on understanding and targeting extrachromosomal DNA (ecDNA), a key driver of oncogene amplification, tumor progression, and treatment resistance in many intractable cancers. By exploiting the unique vulnerabilities of cancer cells that rely on ecDNA, Boundless Bio is advancing a pipeline of ecDNA-directed therapies (ecDTx). The company aims to provide novel, life-improving treatment options for a patient population with significant unmet medical needs, as cancers driven by oncogene amplification are often unresponsive to existing targeted therapies and immunotherapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Boundless Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Boundless Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Boundless Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
